The different impact of BRCA mutations on the survival of epithelial ovarian cancer patients: a retrospective single-center experience.
OBJECTIVE
The objective of this study was to examine whether the oncologic outcomes of BRCA1-associated and BRCA2-associated ovarian cancers correlate differently.


METHODS
Genetic data and clinical characteristics were correlated with progression-free survival (PFS) and overall survival (OS).


RESULTS
Data from 147 BRCA-mutated patients (119 BRCA1-positive and 28 BRCA2-positive) were analyzed. At a median follow-up of 69 months, the median PFS was 27.2 and 45.46 months for BRCA1 and BRCA2 patients, respectively (p = 0.03). Median OS was 77.23 and 111.47 months for BRCA1 and BRCA2 patients, respectively (p = 0.08).


CONCLUSIONS
BRCA2 mutations confer PFS and a trend to OS advantage compared with the BRCA1 mutation in BRCA-mutated epithelial ovarian cancer patients.
Gynecologic Oncology Unit, Fondazione 'IRCCS' National Cancer Institute, Milan, Italy.
D
D
Lorusso
F
F
Cirillo
M
M
Mancini
G B
GB
Spatti
B
B
Grijuela
A
A
Ditto
F
F
Raspagliesi
D000230:Adenocarcinoma / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D000328:Adult; D000368:Aged; D019313:BRCA1 Protein / Q000235:genetics*; D024682:BRCA2 Protein / Q000235:genetics*; D000077216:Carcinoma, Ovarian Epithelial; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D015999:Multivariate Analysis; D009375:Neoplasms, Glandular and Epithelial / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D016016:Proportional Hazards Models; D012189:Retrospective Studies
D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D024682:BRCA2 Protein; C551750:BRCA2 protein, human